Methoxy polyethylene glycol-epoetin beta is a synthetic erythropoiesis stimulating agent (ESA) used to treat anemia associated with chronic kidney disease. A medication used to treat anemia, or reduced healthy red blood cells, due to a long-term kidney disease.
- Mechanism
- Curator reviewed
Erythropoietin is a growth factor for erythroid development. It is produced in the kidney and released into the bloodstream in response to hypoxia, interacting with erythroid progenitor cells to increase red blood cell production. Production of endogenous erythropoietin is impaired in patients with chronic kidney disease (CKD), and erythropoietin deficiency is the primary cause of their anaemia. Administration of methoxy polyethylene glycol-epoetin beta acts like endogenous erythropoetin and stimulates erythropoetin receptor of the erythroid progenitor cells in the bone marrow.
- Primary indication
- For the treatment of patients with anaemia associated with chronic kidney disease.Curator reviewed · 1 structured indication
- First approval
- Canada, 2008 · United States, 2014 · European Union, 2016
- Also known as
- CERA · Pegzerepoetin alfa
- Code names
- R-744
- Brand names
Resolves to
What you can answer from here — as of September 13, 2026
Which drugs share a target with Methoxy polyethylene glycol-epoetin beta, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account